Stock AnalizCharles River Laboratories International, Inc. CRL
Biotechnology: Commercial Physical & Biological Resarch · IPO 2000 · data as of November 13, 2026
Charles River Laboratories International, Inc. (CRL) is a healthcare company listed in the US with a market value of about $16.2B. In the twelve months to September 26, 2026 it had revenue of $4.0B and net income of $40M, a net margin of 1.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).
Key numbers: a P/E of 348.4, a price to free cash flow of 40.5, 5-year revenue growth of 7% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 76% below the current price.
Score: 1.2 / 5
Checks passed
- 3-year free cash flow growth above 10% a year
- Positive free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B | $2.9B | $2.6B | $2.3B | $1.9B | $1.7B |
| Net income | $40M | -$144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M |
| Free cash flow | $400M | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $262M |
| EPS (diluted) | $0.97 | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 |
| Net margin | 1.0% | -3.6% | 0.5% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% |
| ROIC | — | 0.3% | 2.9% | 7.6% | 8.4% | 8.9% | 8.3% | 8.0% | 8.7% | 10.5% | 8.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $350.57, 4% above the current price; targets range from $145.00 to $400.00; the consensus rating is “Buy”; expected EPS is $11.47 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Charles River Laboratories International’s P/E ratio?
About 348.4, based on the last twelve months of diluted earnings per share (forward P/E about 26.7).
Is Charles River Laboratories International stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 76% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Charles River Laboratories International pay a dividend?
Not currently.
Is Charles River Laboratories International a good stock to buy?
We do not give buy or sell advice. Charles River Laboratories International scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.